Home
Kenya BioVax Institute Limited (KBI)

Kenya BioVax Institute L... Market Share Analysis for July 2026

Industry: N/A

Domainbiovax.go.ke

Year Founded2022

Employees201 - 500

Annual Revenue--

Kenya BioVax Institute Limited (KBI)

Kenya BioVax Institute Limited (KBI) (including company regionals)

biovax.go.ke

See more website traffic and engagement information

Total visits to Kenya BioVax Institute Limited (KBI)'s top domains

Understand Kenya BioVax Institute Limited (KBI) market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

biovax.go.ke3.7K

See more with Sales Intelligence

Avg. visit duration in Kenya BioVax Institute Limited (KBI)'s top domains

Analyze Kenya BioVax Institute Limited (KBI) engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

biovax.go.ke00:05:31

See more with Sales Intelligence

Avg. pageviews on Kenya BioVax Institute Limited (KBI)'s top domains

See how Kenya BioVax Institute Limited (KBI) keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

biovax.go.ke5.83

See more with Sales Intelligence

Kenya BioVax Institute Limited (KBI) top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Kenya BioVax Institute Limited (KBI)

These are the website technologies, by industry, used by Kenya BioVax Institute Limited (KBI) top domains

Widget (10)

Twemoji

Payment & Currencies (5)

PayPal

Social (4)

Instagram

Content Management System (3)

WordPress

More Technologies

9

See all

News & Signals from Kenya BioVax Institute Limited (KBI)

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBioVax expands facilities to Kenya, Eastern Africa, Africa.Kenya is scaling up vaccine manufacturing through the BioVax Institute, a $60.8 million (Ksh7.85 billion) fill-and-finish facility projected to produce up to 72 million doses annually, plus a $248 million (Ksh32.03 billion) end-to-end plant at Konza Technopolis.

NewsBioVax attends event Ninth Tokyo International Conference.The initiative, led by the state-owned Kenya BioVax Institute, is a cornerstone of the country's long-term health strategy and a significant topic of discussion on the global stage, including at the recent Ninth Tokyo International Conference on African Development (TICAD9).